Fusen Pharmaceutical Company Limited
HKSE: 1652.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Zhiming Cao
- Employees
- 1,131
- Headquarters
- Nanyang, China
- IPO year
- 2018
- Market cap
- HK$865.0M
- Website
- https://www.fusenyy.com
Loading 1652…
Loading profile data…Frequently asked questions about 1652
What does Fusen Pharmaceutical Company Limited (1652.HK) do?
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and c...
Where does 1652.HK trade?
Fusen Pharmaceutical Company Limited (1652.HK) trades on the Hong Kong Stock Exchange.
What sector is 1652.HK in?
Fusen Pharmaceutical Company Limited (1652.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Fusen Pharmaceutical Company Limited?
Zhiming Cao is the chief executive officer of Fusen Pharmaceutical Company Limited (1652.HK).
Where is Fusen Pharmaceutical Company Limited headquartered?
Fusen Pharmaceutical Company Limited is headquartered in China.
Does 1652.HK pay a dividend?
Fusen Pharmaceutical Company Limited (1652.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1652.HK go public?
Fusen Pharmaceutical Company Limited (1652.HK) completed its initial public offering in 2018.